Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar;53(6):766-767.
doi: 10.1111/apt.16287.

Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply

Aysha H Al-Ani  1 , Ralley E Prentice  1 , Clarissa Rentsch  1 , Britt Christensen  1
Affiliations
Comment

Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply

Aysha H Al-Ani et al. Aliment Pharmacol Ther. 2021 Mar.

Abstract

LINKED CONTENT

This article is linked to Al‐Ani et al and Privitera et al papers. To view these articles, visit https://doi.org/10.1111/apt.15779 and https://doi.org/10.1111/apt.16297

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

References

    1. Privitera G, Pugliese D, Scaldaferri F, Armuzzi A. Letter: SARS‐CoV‐2 infection in two IBD patients treated with dual targeted therapy. Aliment Pharmacol Ther. 2021;53:764–765. - PMC - PubMed
    1. Privitera G, Onali S, Pugliese D, et al. Dual targeted therapy: a possible option for the management of refractory inflammatory bowel disease. J Crohns Colitis. 2020. 10.1093/ecco-jcc/jjaa149 - DOI - PubMed
    1. Kwapisz L, Raffals LE, Bruining DH, et al. Combination biologic therapy in inflammatory bowel disease: experience from a tertiary care center. Clin Gastroenterol Hepatol. 2020. 10.1016/j.cgh.2020.02.017 - DOI - PubMed
    1. Yang E, Panaccione N, Whitmire N, et al. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Aliment Pharmacol Ther. 2020;51:1031‐1038. - PMC - PubMed
    1. Sands BE, Kozarek R, Spainhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007;13:2‐11. - PubMed